Mereo BioPharmaMREO
About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Employees: 33
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
41% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $2.26M
20% more capital invested
Capital invested by funds: $363M [Q2] → $435M (+$71.9M) [Q3]
0.61% less ownership
Funds ownership: 14.36% [Q2] → 13.75% (-0.61%) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
3% less funds holding
Funds holding: 79 [Q2] → 77 (-2) [Q3]
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
LifeSci Capital Cory Jubinville 100% 1-year accuracy 1 / 1 met price target | 162%upside $10 | Outperform Initiated | 24 Dec 2024 |
Jefferies Maury Raycroft 0% 1-year accuracy 0 / 10 met price target | 84%upside $7 | Buy Initiated | 6 Dec 2024 |
Needham Gil Blum 18% 1-year accuracy 29 / 164 met price target | 84%upside $7 | Buy Reiterated | 12 Nov 2024 |
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target | 84%upside $7 | Overweight Reiterated | 1 Oct 2024 |